Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;5(3):278-87.
doi: 10.5009/gnl.2011.5.3.278. Epub 2011 Aug 18.

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B

Soon Sun Kim  1 , Jae Youn Cheong, Sung Won Cho
Affiliations

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B

Soon Sun Kim et al. Gut Liver. 2011 Sep.

Abstract

Although the prevalence of chronic hepatitis B has decreased considerably in recent years due to widespread use of the hepatitis B virus (HBV) vaccine, its prevalence still remains high in adults, and this can place a significant burden on health care in areas with endemic HBV. Since the introduction of nucleos(t)ide analogues (NUCs), there has been marked improvement in the care of patients with chronic hepatitis B, resulting in increased survival. However, the emergence of drug resistance in patients treated with NUCs is a major concern. The number of multi-drug resistant patients is increasing, and many patients may not respond to the currently available drugs. In this review, we describe the current status of NUC therapy for antiviral-naïve and -resistant patients.

Keywords: Chronic hepatitis B; Drug resistance; Hepatitis B virus; Nucleos(t)ide analogue.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

References

    1. Kim SB, Lee WK, Choi H, et al. A study on viral hepatitis markers and abnormal liver function test in adults living in northwest area of Chungnam. Korean J Gastroenterol. 2009;53:355–360. - PubMed
    1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242. - PubMed
    1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662. - PubMed
    1. DiBisceglie A, Lai CL, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside treated hepatitis B patients. Hepatology. 2006;44(Suppl 1):230A.
    1. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. - PubMed

LinkOut - more resources